We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Lockheed, Northrop Grumman, Heico and Wesco
Read MoreHide Full Article
For Immediate Release
Chicago, IL –July 23, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Lockheed Martin Corp. (LMT - Free Report) , Northrop Grumman Corp. (NOC - Free Report) , Heico Corp. (HEI - Free Report) and Wesco Aircraft Holdings .
Here are highlights from Monday’s Analyst Blog:
U.S. House Passes 2020 Defense Bill: 4 Stocks to Buy
The U.S. House of Representatives recently passed a $733 billion defense policy bill, $17 billion short of the proposed Republican-led Senate bill.
The proposal to allocate $17 billion for building a wall on the border with Mexico was voted against by the Democrat-held House, which instead stressed on deploying troops to the border.
Highlights of the Budget Plan
Of the total, $718.3 billion is being kept as funding for the Pentagon, reflecting 4.7% real growth over the initial fiscal 2019 President’s budget. The budget proposal includes critical funding for Overseas Contingency Operations (OCO) and an emergency budget request, totaling $173.8 billion.
It emphasizes on increasing the end strength for the U.S. Army, Navy and Air Force to 33,600, 29.7% over the fiscal 2019 budget. Here, 30,300 are being kept as active components with the largest increase in the Air Force domain, and 3,300 for reserve components, with the highest increase in the Army Guard and Reserve.
Interestingly, the proposed budget reflects increased spending plans of a whopping $57.7 billion on Aircraft, 166% higher than the previous year’s budget. Notably, $34.7 billion has been allotted to Shipbuilding, showcasing an 89.6% surge over the prior fiscal year.
Similarly, spending plans on other domains have seen a rise that includes a higher allotment of $31 billion for multi-domain and nuclear triad, $14.6 billion for Ground Systems, $14.1 for space and $9.6 billion for cyber.
Defense Stocks Likely to Benefit
The expansionary budgetary policy reform, likely to be adopted by the U.S. administration, should encourage investors to add top-performing defense stocks. In line with this, we have shortlisted four defense stocks that have outperformed the Zacks Aerospace sector year to date, possess a Zacks Rank #1 (Strong Buy) or 2 (Buy) and compelling earnings growth expectations. You can see the complete list of today’s Zacks #1 Rank stocks here.
Lockheed Martin Corp., a Zacks Rank #1 stock, has gained 36.4% year to date compared to the sector's growth of 25.8%. It has an estimated long-term earnings growth rate of 7%.
Northrop Grumman Corp., a Zacks Rank #2 stock, has rallied 31.6% year to date. It has an estimated long-term earnings growth rate of 12.8%.
Heico Corp., a Zacks Rank #1 stock, has gained 77% year to date. It has an estimated long-term earnings growth rate of 13.9%.
Wesco Aircraft Holdings, a Zacks Rank #2, has gained 36.7% year to date. It has an estimated long-term earnings growth rate of 12%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Lockheed, Northrop Grumman, Heico and Wesco
For Immediate Release
Chicago, IL –July 23, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Lockheed Martin Corp. (LMT - Free Report) , Northrop Grumman Corp. (NOC - Free Report) , Heico Corp. (HEI - Free Report) and Wesco Aircraft Holdings .
Here are highlights from Monday’s Analyst Blog:
U.S. House Passes 2020 Defense Bill: 4 Stocks to Buy
The U.S. House of Representatives recently passed a $733 billion defense policy bill, $17 billion short of the proposed Republican-led Senate bill.
The proposal to allocate $17 billion for building a wall on the border with Mexico was voted against by the Democrat-held House, which instead stressed on deploying troops to the border.
Highlights of the Budget Plan
Of the total, $718.3 billion is being kept as funding for the Pentagon, reflecting 4.7% real growth over the initial fiscal 2019 President’s budget. The budget proposal includes critical funding for Overseas Contingency Operations (OCO) and an emergency budget request, totaling $173.8 billion.
It emphasizes on increasing the end strength for the U.S. Army, Navy and Air Force to 33,600, 29.7% over the fiscal 2019 budget. Here, 30,300 are being kept as active components with the largest increase in the Air Force domain, and 3,300 for reserve components, with the highest increase in the Army Guard and Reserve.
Interestingly, the proposed budget reflects increased spending plans of a whopping $57.7 billion on Aircraft, 166% higher than the previous year’s budget. Notably, $34.7 billion has been allotted to Shipbuilding, showcasing an 89.6% surge over the prior fiscal year.
Similarly, spending plans on other domains have seen a rise that includes a higher allotment of $31 billion for multi-domain and nuclear triad, $14.6 billion for Ground Systems, $14.1 for space and $9.6 billion for cyber.
Defense Stocks Likely to Benefit
The expansionary budgetary policy reform, likely to be adopted by the U.S. administration, should encourage investors to add top-performing defense stocks. In line with this, we have shortlisted four defense stocks that have outperformed the Zacks Aerospace sector year to date, possess a Zacks Rank #1 (Strong Buy) or 2 (Buy) and compelling earnings growth expectations. You can see the complete list of today’s Zacks #1 Rank stocks here.
Lockheed Martin Corp., a Zacks Rank #1 stock, has gained 36.4% year to date compared to the sector's growth of 25.8%. It has an estimated long-term earnings growth rate of 7%.
Northrop Grumman Corp., a Zacks Rank #2 stock, has rallied 31.6% year to date. It has an estimated long-term earnings growth rate of 12.8%.
Heico Corp., a Zacks Rank #1 stock, has gained 77% year to date. It has an estimated long-term earnings growth rate of 13.9%.
Wesco Aircraft Holdings, a Zacks Rank #2, has gained 36.7% year to date. It has an estimated long-term earnings growth rate of 12%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.